Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
47
EDSA Quote, Financials, Valuation and Earnings
Last price:
$4.28
Seasonality move
:
-21.95%
Day range:
$2.42 - $4.35
52-week range:
$0.72 - $4.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
31.22x
P/B ratio:
7.78x
Volume:
29.9M
Avg. volume:
6.6M
1-year change:
111.17%
Market cap:
$36.3M
Revenue:
--
EPS (TTM):
-$1.15
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 23.24% | 31.9% | $17.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | -42.53% | -- | $3.75 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.06 | -- | -9.85% | $5.54 |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -- | -- | -- | $64.52 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.21 | -100% | -40.06% | $56.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EDSA
Edesa Biotech, Inc.
|
$4.35 | $11.00 | $36.3M | -- | $0.00 | 0% | 31.22x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$14.15 | $17.00 | $1.9B | 6.81x | $0.00 | 0% | 6.93x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.68 | $3.75 | $16.8M | -- | $0.00 | 0% | 24.81x |
|
ONCY
Oncolytics Biotech, Inc.
|
$1.04 | $5.54 | $111.9M | -- | $0.00 | 0% | -- |
|
PMN
ProMIS Neurosciences, Inc.
|
$24.60 | $64.52 | $52.9M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$43.79 | $56.50 | $3.4B | -- | $0.00 | 0% | 462.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EDSA
Edesa Biotech, Inc.
|
-- | -2.737 | -- | 16.51x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
11.4% | 0.024 | 3.56% | 4.69x |
|
LEXX
Lexaria Bioscience Corp.
|
2.03% | -0.580 | 0.43% | 3.04x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.535 | 0.41% | 1.61x |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -1.698 | -- | 1.26x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.35% | -0.408 | 0.23% | 13.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EDSA
Edesa Biotech, Inc.
|
-$25.5K | -$2.3M | -66.98% | -66.98% | -- | -$2.1M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$68.3M | $28.2M | 59.78% | 71.44% | 36.52% | $44.5M |
|
LEXX
Lexaria Bioscience Corp.
|
-$24.2K | -$1.6M | -186.06% | -189.86% | -2155.4% | -$989.2K |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -$11.8M | -348.3% | -348.3% | -- | -$10.2M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$611K | -$109.8M | -52.78% | -53.48% | -969.84% | -$79.4M |
Edesa Biotech, Inc. vs. Competitors
-
Which has Higher Returns EDSA or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of 42.95%. Edesa Biotech, Inc.'s return on equity of -66.98% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 71.44%.
Company Gross Margin Earnings Per Share Invested Capital EDSAEdesa Biotech, Inc.-- -$0.28 $14M AUPHAurinia Pharmaceuticals, Inc.88.59% $1.53 $656.1M -
What do Analysts Say About EDSA or AUPH?
Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 152.87%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 20.14%. Given that Edesa Biotech, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EDSAEdesa Biotech, Inc.2 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is EDSA or AUPH More Risky?
Edesa Biotech, Inc. has a beta of 0.049, which suggesting that the stock is 95.095% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.535, suggesting its more volatile than the S&P 500 by 53.466%.
-
Which is a Better Dividend Stock EDSA or AUPH?
Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDSA or AUPH?
Edesa Biotech, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $77.1M. Edesa Biotech, Inc.'s net income of -$2.2M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $210.8M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 6.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus 6.93x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M AUPHAurinia Pharmaceuticals, Inc.6.93x 6.81x $77.1M $210.8M
-
Which has Higher Returns EDSA or LEXX?
Lexaria Bioscience Corp. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of -2178.51%. Edesa Biotech, Inc.'s return on equity of -66.98% beat Lexaria Bioscience Corp.'s return on equity of -189.86%.
Company Gross Margin Earnings Per Share Invested Capital EDSAEdesa Biotech, Inc.-- -$0.28 $14M LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M -
What do Analysts Say About EDSA or LEXX?
Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 152.87%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $3.75 which suggests that it could grow by 455.56%. Given that Lexaria Bioscience Corp. has higher upside potential than Edesa Biotech, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EDSAEdesa Biotech, Inc.2 0 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is EDSA or LEXX More Risky?
Edesa Biotech, Inc. has a beta of 0.049, which suggesting that the stock is 95.095% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.863%.
-
Which is a Better Dividend Stock EDSA or LEXX?
Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDSA or LEXX?
Edesa Biotech, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is lower than Lexaria Bioscience Corp.'s net income of -$1.6M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus 24.81x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M LEXXLexaria Bioscience Corp.24.81x -- -- -$1.6M
-
Which has Higher Returns EDSA or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of --. Edesa Biotech, Inc.'s return on equity of -66.98% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital EDSAEdesa Biotech, Inc.-- -$0.28 $14M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About EDSA or ONCY?
Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 152.87%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.54 which suggests that it could grow by 432.25%. Given that Oncolytics Biotech, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EDSAEdesa Biotech, Inc.2 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is EDSA or ONCY More Risky?
Edesa Biotech, Inc. has a beta of 0.049, which suggesting that the stock is 95.095% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.708%.
-
Which is a Better Dividend Stock EDSA or ONCY?
Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDSA or ONCY?
Edesa Biotech, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns EDSA or PMN?
ProMIS Neurosciences, Inc. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of --. Edesa Biotech, Inc.'s return on equity of -66.98% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.
Company Gross Margin Earnings Per Share Invested Capital EDSAEdesa Biotech, Inc.-- -$0.28 $14M PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M -
What do Analysts Say About EDSA or PMN?
Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 152.87%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $64.52 which suggests that it could grow by 162.27%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EDSAEdesa Biotech, Inc.2 0 0 PMNProMIS Neurosciences, Inc.2 0 0 -
Is EDSA or PMN More Risky?
Edesa Biotech, Inc. has a beta of 0.049, which suggesting that the stock is 95.095% less volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.225, suggesting its less volatile than the S&P 500 by 122.489%.
-
Which is a Better Dividend Stock EDSA or PMN?
Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDSA or PMN?
Edesa Biotech, Inc. quarterly revenues are --, which are smaller than ProMIS Neurosciences, Inc. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is higher than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M
-
Which has Higher Returns EDSA or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of -867.29%. Edesa Biotech, Inc.'s return on equity of -66.98% beat Xenon Pharmaceuticals, Inc.'s return on equity of -53.48%.
Company Gross Margin Earnings Per Share Invested Capital EDSAEdesa Biotech, Inc.-- -$0.28 $14M XENEXenon Pharmaceuticals, Inc.-- -$1.31 $589.7M -
What do Analysts Say About EDSA or XENE?
Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 152.87%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $56.50 which suggests that it could grow by 29.03%. Given that Edesa Biotech, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EDSAEdesa Biotech, Inc.2 0 0 XENEXenon Pharmaceuticals, Inc.18 0 0 -
Is EDSA or XENE More Risky?
Edesa Biotech, Inc. has a beta of 0.049, which suggesting that the stock is 95.095% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.665%.
-
Which is a Better Dividend Stock EDSA or XENE?
Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDSA or XENE?
Edesa Biotech, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$105.3M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus 462.74x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M XENEXenon Pharmaceuticals, Inc.462.74x -- -- -$105.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
